Fast Five Quiz: Non–Small Cell Lung Cancer (NSCLC) and the Epidermal Growth Factor Receptor Gene (EGFR)

Daniel S. Schwartz, MD, MBA


November 30, 2021

T790M is associated with resistance to first- and second-generation EGFR TKIs. However, third-generation TKIs are generally effective in patients with progression on first- or second-generation TKI when T790M as the primary mechanism of resistance.

Treatment options for patients with adenocarcinomas that have EGFR mutations consistent with TKI sensitivity include single-agent targeted therapy with osimertinib, erlotinib, afatinib, gefitinib, or dacomitinib. These patients have been shown to have a significantly better response to targeted therapies than those without these mutations. Current data suggest that tumors without sensitizing EGFR mutations should not be targeted with EGFR TKIs in any line of therapy. Exon 19 deletions and L858R point mutation in exon 21 are associated with responsiveness to TKI therapy.

Learn more about the management of NSCLC and EGFR.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.